NK 171（依托泊苷）治疗恶性淋巴瘤和急性白血病的II期研究。血液系统恶性肿瘤NK 171合作研究组
[Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies].
作者信息
Kimura K, Yamada K, Yoshida T
出版信息
Gan To Kagaku Ryoho. 1986 Mar;13(3 Pt 1):496-501.
A Phase II clinical trial of NK 171 (Etoposide), a semisynthetic podophyllotoxin, was undertaken in 56 patients with advanced malignant lymphoma and 36 patients with acute leukemia. The dosage of NK 171 was 110-130 mg/m2 day p.o. or 80-100 mg/m2 day i.v. for 5 consecutive days. Of the 92 patients, 23.9% obtained a complete or partial remission. By tumor type, good responses were obtained in non-Hodgkin's lymphoma (34%, 17/50), Hodgkin's disease (25%, 1/4), AML (21.4%, 3/14), and CML-BC (25%, 1/4). Side effects included leukopenia (78.4%), alopecia (62.0%), anorexia (40.2%), nausea (30.4%) thrombocytopenia (25.6%) and fever (16.3%). These results demonstrated NK 171 to be an effective agent against malignant lymphoma and acute myeloblastic leukemia.
对56例晚期恶性淋巴瘤患者和36例急性白血病患者进行了半合成鬼臼毒素NK 171（依托泊苷）的II期临床试验。NK 171的剂量为口服110 - 130mg/m²/天或静脉注射80 - 100mg/m²/天，连续5天。92例患者中，23.9%获得完全或部分缓解。按肿瘤类型划分，非霍奇金淋巴瘤（34%，17/50）、霍奇金病（25%，1/4）、急性髓细胞白血病（21.4%，3/14）和慢性粒细胞白血病急变期（25%，1/4）有较好的反应。副作用包括白细胞减少（78.4%）、脱发（62.0%）、厌食（40.2%）、恶心（30.4%）、血小板减少（25.6%）和发热（16.3%）。这些结果表明NK 171是一种治疗恶性淋巴瘤和急性髓细胞白血病的有效药物。
Zotero 插件